Abstract
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1, used in the treatment of different cancer types. A warning has been issued by the European Medicine Agency regarding the risk of Steven-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with atezolizumab. Along with acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS), SJS and TEN are classified as severe cutaneous adverse reactions (SCARs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
